Afghanistan vs Lebanon: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Afghanistan
- Lebanon
How they compare
Afghanistan currently reports 123.58 deaths against 101 deaths in Lebanon, a difference of 22.58 deaths.
That makes Afghanistan's figure about 1.2 times Lebanon's.
The two have swapped places 1 time across 33 shared years of data; in 1990 it was Lebanon ahead.
Afghanistan ranks 123rd and Lebanon ranks 125th of 157 countries.
Across the 4 decades both report, Afghanistan averaged higher in 1 and Lebanon in 2.
Head to head by decade
| Decade | Afghanistan | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 0.4161 deaths | 23.6 deaths | 23.18 deaths | Lebanon |
| 2010s | 58.68 deaths | 68.4 deaths | 9.72 deaths | Lebanon |
| 2020s | 106.72 deaths | 98.67 deaths | 8.05 deaths | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Afghanistan or Lebanon?
- Afghanistan, at 123.58 deaths against 101 deaths in Lebanon as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Afghanistan and Lebanon?
- 22.58 deaths, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Lebanon?
- 33 years are reported by both, from 1990 to 2022.
- How do Afghanistan and Lebanon rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Afghanistan ranks 123rd and Lebanon ranks 125th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.